Rapid developments in methods for cardiovascular (CV) disease risk evaluation and recent advances in pharmacological and procedural strategies for management of cardiometabolic risk factors have significantly improved our ability to identify and treat at-risk patients. Join our internationally renowned faculty for updates on contemporary understanding of cardiovascular disease risk algorithms, polygenic risk scores, biomarkers and CV risk, preventive imaging, and female specific risk factors and learn how to incorporate strategies for personalization of risk assessment for each of your unique patients. Develop skills in recognizing the early, multi-system signs of cardiometabolic disease beyond the heart, including metabolic liver and renal diseases and consider newer pharmacological strategies for organ protection. Targeting obesity is now imperative, particularly in at-risk patients early in the cardiometabolic continuum. Advance your skills in designing a comprehensive management strategy that includes lifestyle, as well as groundbreaking anti-obesity medications and surgical approaches to weight management. The landscape of lipid pharmacotherapy has never been more expansive and the most recent expert guidance on incorporation of these agents into clinical practice will be considered. Presentations of complex patient cases from the real-world will stimulate challenging discussions among participants and expert panelists. And just to keep you at the absolute peak of your scientific evidence game, join us for a session on the Top Trials of 2023-24 in preventive cardiology and cardiometabolic health that will impact your patient care!
LEARNING OBJECTIVES
At the completion of this conference, participants should be able to:
- Incorporate comprehensive cardiovascular risk assessment into routine clinical practice and personalize evaluation based on the patient’s unique risk profile.
- Formulate treatment strategies to target obesity early in the cardiometabolic risk continuum.
- Select pharmacotherapy for management of dyslipidemia and reduction of cardiovascular risk based on current scientific evidence and expert guidance.
- Intervene early for renal and hepatic protection in patients with cardiometabolic disease.
The Medical University of South Carolina (MUSC) Frontiers in Preventive Cardiology and Cardiometabolic Health 2024 conference is designed for a wide range of healthcare professionals interested in preventive cardiology and cardiometabolic health. The target audience includes:
- Cardiologists
- Endocrinologists
- Primary care physicians
- Nurse practitioners
- Physician assistants
- Pharmacists
- Allied health professionals
This conference focuses on the latest advancements in cardiovascular disease risk evaluation, pharmacological strategies, and comprehensive management of cardiometabolic risk factors.
+ Topics:
A New Era in Renal Protection in Cardiometabolic Disease.mp4
Bariatric Surgery Update.mp4
Big Questions About Lipoprotein “Little” (a).mp4
Changing the Paradigm The Top Recent Trials in Preventive Cardiology and Cardiometabolic Health.mp4
Clear Outcomes – The First (and Only) Trial in Statin Intolerant Patients.mp4
Complex Case Discussion Dyslipidemia Management.mp4
Complex Case Discussion Familial Hypercholesterolemia.mp4
Effects of Dietary Sodium on Systolic Blood Pressure in Middle-Aged Individuals A Randomized Order Cross-Over Trial.mp4
Evolving Therapies in Dyslipidemia, ASCVD Risk Reduction Putting It All Together in High-Risk Patients.mp4
Managing the Cardiometabolic Health of Two or More (!)- Hypertensive Disorders of Pregnancy.mp4
MASH, MASLD, MetALD New Names, New Insights in Liver Disease.mp4
Metabolic Syndrome Missed Windows of Opportunity.mp4
Panel Discussion on Bariatric Surgery and Therapies for Obesity Treatment.mp4
Panel Discussion on CV Risk Assessment, Management of Women with CV Risk, and PREVENT Calculator.mp4
Panel Discussion on MASLD Management, SGLT2 inhibitors, Obesity and Sleep Apnea.mp4
Panel Discussion on Top Recent Trials in Preventive Cardiology and Cardiometabolic Health.mp4
Panel Discussion on Treatments of Type 2 Diabetes and Obesity.mp4
Patients in Cardiometabolic Jeopardy Evolving Strategies for Cardiovascular Disease Risk Assessment.mp4
Pictures Are Worth 1,000 Words- The Role of Imaging in CV Risk Assessment and Risk Management.mp4
Refining Management of Women at Risk Female Specific Risk Factors.mp4
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes The SELECT Trial.mp4
Targeting Triglyceride-rich Lipoproteins and Their Remnants.mp4
The Most Important Voice of All Learning to Hear the Patient’s Perspective.mp4
The Top Clinical Trials in Preventive Cardiology VERVE 101.mp4
Weight Management for CVD and Heart Failure.mp4
When Lifestyle Alone Misses the Mark Pharmacological Advances for Management of Obesity.mp4
When You Just Can’t Seem to Sleep It Off- Cardiovascular Risk and Sleep Apnea.mp4
Where Lie the Keys to Treatment of Type 2 Diabetes Mellitus Finding the Perfect Fit in Comprehensive Diabetes Treatment.mp4